Covid: Europe begins studying the Sanofi vaccine file

Things are progressing… While France is concerned about the possibility of a fourth pandemic wave and the controversy over vaccines continues to infinity, the European Medicines Agency announced on Tuesday the launch of the ongoing review procedure for the Sanofi vaccine against Covid. A step for the French laboratory, which was not able to simultaneously deliver effective doses with the actors in the RNA vaccines – Pfizer / BioNTech and Moderna.

The decision by European health authorities to begin the procedure that paves the way for a possible marketing authorization is based on preliminary preclinical and clinical findings, which are findings “indicating that the vaccine leads to the production of antibodies and can help protect against disease,” according to the agency. The latter will continue the procedure until it has enough information for the laboratory to make a formal application for a marketing authorization.

The results of the third stage main

This type of permit, which has already benefited several vaccines against Covid, (J&J, Sinovac…) saves time in examining the registration file, even if the results of the third stage are still necessary. Sanofi arrived too late in the battle against the pandemic, having had to replay Phase Two after a dose error, with a hopeful vaccine at the end of the year. Thus he is trying to save time by all means, hoping that his vaccine will be used as a third booster dose against variants.

Health authorities seem to consider that the third dose may be different from the first two, and the goal is to stimulate the immune system regardless of the means. So far, there does not seem to be any conflict between vaccines based on different technologies (RNA, adenovirus, etc.).